logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
E

Evan R. Rogers

Department of Biomedical Engineering

6H指数
21论文数
169被引数
收录论文 26
发表时间
logo
Longitudinal Changes in Sensory Processing and Clinical Outcomes During Spinal Cord and Dorsal Root Ganglion Stimulation to Treat Chronic Pain: A Pilot Study脊髓和背根神经节刺激治疗慢性疼痛期间感觉处理和临床结果的纵向变化：一项初步研究
errJournal of Pain Research
IF2.5
err2025-08-29
err0
errOAAI
errEvan R Rogers; Vishwanath Sankarasubramanian; Wutt Hmone T Kyi; Ehsan Mirzakhalili; Carlos J Anaya; Jessica Loechli; Steven E Harte; Parag G Patil; Srinivas Chiravuri; Scott F Lempka
err分享
err收藏
Enhancing Precision in Chronic Pain Management: A Model-Based Investigation of the Physiological Effects of Spinal Cord Stimulation in a Randomized Controlled Trial增强慢性疼痛管理的精确性：基于随机对照试验的脊髓电刺激生理效应的模型化研究
errBrain Stimulation
IF8.4
err2025-08-05
err0
errOAAI
errWutt Hmone T. Kyi; Adrian Porras Laura; Evan R. Rogers; Jessica N. Loechli; Steven E. Harte; Srinivas Chiravuri; Parag G. Patil; Scott F. Lempka
err分享
err收藏
BH-30236, a Novel Macrocyclic Clk Inhibitor Modulating Aberrant RNA Splicing, Demonstrates Potent Anti-Cancer Activity Against Myeloid MalignanciesBH-30236，一种新型大环CLK抑制剂，可通过调节异常RNA剪接，对髓系恶性肿瘤显示出强大的抗肿瘤活性。
errBLOOD
IF23.1
err2024-11-05
err0
PREAI
errDeng, Wei; Jiang, Ping; Li, Danan; Zhai, Dayong; Ling, Nancy; Wang, Zhenping; Hu, Yue; Rogers, Evan; Darjania, Levan; Whitten, Jeff; Shao, Jesse; Montalban, Antonio; Rui, Eugene; Cui, J. Jean
err分享
err收藏
Discovery of BH-30236: A novel macrocyclic CLK inhibitor targeting alternative splicing in cancers
errCANCER RESEARCH
IF16.6
err2024-03-22
err0
PREAI
errCui, J. Jean; Jiang, Ping; Deng, Wei; Zhai, Dayong; Ling, Nancy; Li, Danan; Wang, Zhenping; Hu, Yue; Darjania, Levan; Whitten, Jeff; Rogers, Evan; Rui, Eugene
err分享
err收藏
Does high-frequency stimulation of sensory axons break the causal link between pain relief and paresthesia?
errNEURON
IF15
err2024-02-01
err1
errOAAI
errRogers, Evan R.; Lempka, Scott F.; Capogrosso, Marco
err分享
err收藏
Model-based analysis of subthreshold mechanisms of spinal cord stimulation for pain基于模型的脊髓阈下刺激疼痛机制分析
errJOURNAL OF NEURAL ENGINEERING
IF3.8
err2023-11-09
err3
errOAAI
errRogers, Evan R.; Mirzakhalili, Ehsan; Lempka, Scott F.
err分享
err收藏
An optimization framework for targeted spinal cord stimulation
errJOURNAL OF NEURAL ENGINEERING
IF3.8
err2023-09-28
err8
errOAAI
errMirzakhalili, Ehsan; Rogers, Evan R.; Lempka, Scott F.
err分享
err收藏
Neural Recruitment During Conventional, Burst, and 10-kHz Spinal Cord Stimulation for Pain常规，突发和10 kHz脊髓刺激疼痛期间的神经募集
errJOURNAL OF PAIN
IF4
err2022-03-01
err20
errOAAI
errRogers, Evan R.; Zander, Hans J.; Lempka, Scott F.
err分享
err收藏
Neuromodulation using ultra low frequency current waveform reversibly blocks axonal conduction and chronic pain
errSCIENCE TRANSLATIONAL MEDICINE
IF14.6
err2021-08-25
err25
PREAI
errJones, Martyn G.; Rogers, Evan R.; Harris, James P.; Sullivan, Andrew; Ackermann, D. Michael; Russo, Marc; Lempka, Scott F.; McMahon, Stephen B.
err分享
err收藏
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
errMOLECULAR CANCER THERAPEUTICS
IF5.5
err2021-06-22
err60
errOAAI
errMurray, Brion W.; Zhai, Dayong; Deng, Wei; Zhang, Xin; Ung, Jane; Nguyen, Vivian; Zhang, Han; Barrera, Maria; Parra, Ana; Cowell, Jessica; Lee, Dong J.; Aloysius, Herve; Rogers, Evan
err分享
err收藏
TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors
errCANCER RESEARCH
IF16.6
err2020-08-15
err15
PREAI
errCui, J. Jean; Rogers, Evan; Zhai, Dayong; Deng, Wei; Ung, Jane; Nguyen, Vivian; Zhang, Han; Zhang, Xin; Parra, Ana; Barrera, Maria; Lee, Dong; Murray, Brion
err分享
err收藏
Realistic anatomically detailed open-source spinal cord stimulation (RADO-SCS) model
errJOURNAL OF NEURAL ENGINEERING
IF3.8
err2020-04-23
err22
errOAAI
errKhadka, Niranjan; Liu, Xijie; Zander, Hans; Swami, Jaiti; Rogers, Evan; Lempka, Scott F.; Bikson, Marom
err分享
err收藏
TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling
errCANCER RESEARCH
IF16.6
err2019-07-01
err3
PREAI
errZhai, Dayong; Rogers, Evan; Deng, Wei; Zhang, Xin; Lee, Dong; Ung, Jane; Zhang, Han; Liu, Jing; Lu, Yuelie; Huang, John; Graber, Armin; Zimmerman, Zach; Lim, John; Whitten, Jeffrey; Cui, J. Jean
err分享
err收藏
Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations
errCANCER RESEARCH
IF16.6
err2019-07-01
err1
PREAI
errDeng, Wei; Zhai, Dayong; Zhang, Xin; Lee, Dong; Rogers, Evan; Whitten, Jeffrey; Cui, J. Jean
err分享
err收藏
TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses
errCANCER RESEARCH
IF16.6
err2019-07-01
err6
PREAI
errDeng, Wei; Zhai, Dayong; Rogers, Evan; Zhang, Xin; Lee, Dong; Ung, Jane; Zhang, Han; Liu, Jing; Lu, Yuelie; Huang, John; Graber, Armin; Zimmerman, Zach; Lim, John; Whitten, Jeffrey; Cui, J. Jean
err分享
err收藏
Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
errCANCER RESEARCH
IF16.6
err2019-07-01
err23
PREAI
errDrilon, Alexander; Zhai, Dayong; Deng, Wei; Zhang, Xin; Lee, Dong; Rogers, Evan; Whitten, Jeffrey; Huang, Zhongdong; Graber, Armin; Liu, Juliet; Stopatschinskaja, Shanna; Cui, J. Jean; Kim, Dong-Wan; Cho, Byoung Chul; Doebele, Robert C.; Ou, Sai-Hong Ignatius; Lee, Jeeyun; Shaw, Alice T.
err分享
err收藏
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
errCANCER DISCOVERY
IF33.3
err2018-10-02
err366
errOAAI
errDrilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lees, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahns, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.
err分享
err收藏
Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK
errCANCER RESEARCH
IF16.6
err2018-07-01
err0
PREAI
errDeng, Wei; Zhai, Dayong; Huang, John; Rogers, Evan; Whitten, Jeffrey; Lim, John; Li, Yishan; Cui, Jean
err分享
err收藏
TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT
errMOLECULAR CANCER THERAPEUTICS
IF5.5
err2018-01-01
err2
PREAI
errZhai, Dayong; Deng, Wei; Rogers, Evan; Huang, Zhongdong; Whitten, Jeffrey; Lim, John; Li, Yishan; Cui, J. Jean
err分享
err收藏
TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623R
errMOLECULAR CANCER THERAPEUTICS
IF5.5
err2018-01-01
err0
PREAI
errCui, J. Jean; Zhai, Dayong; Deng, Wei; Rogers, Evan; Huang, Zhongdong; Whitten, Jeffrey; lim, John; Li, Yishan
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
A
Alice T. Shaw
H 指数: 115 · 论文数: 687
D
D. Ross Camidge
H 指数: 110 · 论文数: 999
S
Stephen B. McMahon
H 指数: 109 · 论文数: 472
M
Myung‐Ju Ahn
H 指数: 109 · 论文数: 1.3K
B
Byoung Chul Cho
H 指数: 106 · 论文数: 1.6K
查看更多